Effects of Chromium Supplementation on Parameters of the Metabolic Syndrome in Patients With Type 2 Diabetes Mellitus

• Status: Completed
• Trial end date: 2005-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether chromium (yeast), is effective in improving glycaemic control and insulin resistance.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medical Research Foundation, The Netherlands
• Collaborator: Pharma Nord
• Treatments: Chromium

Criteria

Inclusion Criteria:

• type 2 diabetes with haemoglobin A1c level between 7 and 8.5% at the last visit

• treated with oral blood glucose lowering therapy, which has not been changed for the last three months.

Exclusion Criteria:

• pregnant women; women trying to become pregnant

• patients with a serum creatinine concentration over 150 micromol/l in men and 120 micromol/l in women, Cockcroft < 50 ml/min

• hepatic enzyme levels (ALAT) over 90 U/l (2 x upper limit)

• patients known with allergy or intolerance for yeast

• patients currently taking chromium supplements

• patients treated with insulin.